BDTX 株価推移チャート
BDTX 財務
Black Diamond Therapeutics Inc
$1.66
-5.68%
$-0.1
終値： Aug 10, 16:00:00 GMT-4
$1.66
0.01%
$0
アフターマーケット：Aug 10, 20:00:00 GMT-4
戻る
Black Diamond Therapeutics Inc (BDTX) 財務
主要データ
前終値
$1.76
始値
$1.76
当日レンジ
$1.64 - $1.77
52週レンジ
$1.6 - $4.94
取引高
869.3K
平均取引高
1.4M
配当利回り
--
1株当たり利益(TTM)
-0.76
時価総額
$95.1M
BDTXとは何ですか？
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
